Literature DB >> 20358422

Serum micronutrient and antioxidant levels at baseline and the natural history of men with localised prostate cancer on active surveillance.

Ramachandran Venkitaraman1, Karen Thomas, Phillip Grace, David P Dearnaley, Alan Horwich, Robert A Huddart, Christopher C Parker.   

Abstract

The aim of this study was to determine whether serum concentrations of micronutrients, antioxidants and vitamins predict rate of disease progression in untreated, localised prostate cancer. Patients with localised prostatic adenocarcinoma on a prospective study of active surveillance underwent monitoring with serial PSA levels and repeat prostate biopsies. Disease progression was defined as either adverse histology on repeat biopsy (primary Gleason grade >or=4 or >50% positive cores of total) or radical treatment for PSA velocity >1 ng ml(-1) year(-1). Time to disease progression was analysed with respect to baseline levels of alpha-tocopherol, gamma-tocopherol, alpha-carotene and beta-carotene, lycopene, retinol and selenium. One hundred four patients were evaluable, with a median follow-up of 2.5 years. Thirty-eight patients experienced disease progression, 13 biochemical and 25 histologic progression. Median time to disease progression was 2.62 years. No significant association was seen between time to disease progression and baseline serum levels of alpha-tocopherol (p = 0.86), gamma-tocopherol (p = 0.84), alpha-carotenoid (p = 0.66), beta-carotene (p = 0.65), lycopene (p = 0.0.15), retinol (p = 0.76) or selenium (p = 0.76). No significant association was seen between serum levels of the micronutrients, antioxidants or vitamins and either adverse histology on repeat biopsy or PSA velocity. Our data do not support the hypothesis that high serum concentrations of micronutrients, antioxidants and vitamins prevent disease progression in men with localised prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20358422     DOI: 10.1007/s13277-009-0013-0

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

Review 1.  Selection of surrogate endpoint biomarkers to evaluate the efficacy of lycopene/tomatoes for the prevention/progression of prostate cancer.

Authors:  Phyllis E Bowen
Journal:  J Nutr       Date:  2005-08       Impact factor: 4.798

2.  Plasma selenium concentration and prostate cancer risk: results from the European Prospective Investigation into Cancer and Nutrition (EPIC).

Authors:  Naomi E Allen; Paul N Appleby; Andrew W Roddam; Anne Tjønneland; Nina Føns Johnsen; Kim Overvad; Heiner Boeing; Steffen Weikert; Rudolf Kaaks; Jakob Linseisen; Antonia Trichopoulou; Gesthimani Misirli; Dimitrios Trichopoulos; Carlotta Sacerdote; Sara Grioni; Domenico Palli; Rosario Tumino; H Bas Bueno-de-Mesquita; Lambertus A Kiemeney; Aurelio Barricarte; Nerea Larrañaga; Maria-José Sánchez; Antonio Agudo; María-José Tormo; Laudina Rodriguez; Pär Stattin; Göran Hallmans; Sheila Bingham; Kay-Tee Khaw; Nadia Slimani; Sabina Rinaldi; Paolo Boffetta; Elio Riboli; Timothy J Key
Journal:  Am J Clin Nutr       Date:  2008-12       Impact factor: 7.045

3.  Lower prostate cancer risk in men with elevated plasma lycopene levels: results of a prospective analysis.

Authors:  P H Gann; J Ma; E Giovannucci; W Willett; F M Sacks; C H Hennekens; M J Stampfer
Journal:  Cancer Res       Date:  1999-03-15       Impact factor: 12.701

4.  Evaluation of the chemopreventive potential of retinoids using a novel in vitro human prostate carcinogenesis model.

Authors:  S T Quader; D Bello-DeOcampo; D E Williams; H K Kleinman; M M Webber
Journal:  Mutat Res       Date:  2001-09-20       Impact factor: 2.433

5.  Relationship between plasma carotenoids and prostate cancer.

Authors:  Shine Chang; John W Erdman; Steven K Clinton; Maya Vadiveloo; Sara S Strom; Yuko Yamamura; Cherie M Duphorne; Margaret R Spitz; Christopher I Amos; John H Contois; Xiangjun Gu; Richard J Babaian; Peter T Scardino; Stephen D Hursting
Journal:  Nutr Cancer       Date:  2005       Impact factor: 2.900

Review 6.  Role of lycopene and tomato products in prostate health.

Authors:  Maria Stacewicz-Sapuntzakis; Phyllis E Bowen
Journal:  Biochim Biophys Acta       Date:  2005-03-13

7.  Vitamin E and selenium supplementation and risk of prostate cancer in the Vitamins and lifestyle (VITAL) study cohort.

Authors:  Ulrike Peters; Alyson J Littman; Alan R Kristal; Ruth E Patterson; John D Potter; Emily White
Journal:  Cancer Causes Control       Date:  2007-10-18       Impact factor: 2.506

Review 8.  Active surveillance with selective delayed intervention is the way to manage 'good-risk' prostate cancer.

Authors:  Laurence Klotz
Journal:  Nat Clin Pract Urol       Date:  2005-03

9.  Decreased incidence of prostate cancer with selenium supplementation: results of a double-blind cancer prevention trial.

Authors:  L C Clark; B Dalkin; A Krongrad; G F Combs; B W Turnbull; E H Slate; R Witherington; J H Herlong; E Janosko; D Carpenter; C Borosso; S Falk; J Rounder
Journal:  Br J Urol       Date:  1998-05

10.  Vitamins E and C in the prevention of prostate and total cancer in men: the Physicians' Health Study II randomized controlled trial.

Authors:  J Michael Gaziano; Robert J Glynn; William G Christen; Tobias Kurth; Charlene Belanger; Jean MacFadyen; Vadim Bubes; JoAnn E Manson; Howard D Sesso; Julie E Buring
Journal:  JAMA       Date:  2008-12-09       Impact factor: 56.272

View more
  2 in total

Review 1.  Increased dietary and circulating lycopene are associated with reduced prostate cancer risk: a systematic review and meta-analysis.

Authors:  J L Rowles; K M Ranard; J W Smith; R An; J W Erdman
Journal:  Prostate Cancer Prostatic Dis       Date:  2017-04-25       Impact factor: 5.554

Review 2.  Nutraceuticals in prostate cancer therapeutic strategies and their neo-adjuvant use in diverse populations.

Authors:  Dominique Reed; Komal Raina; Rajesh Agarwal
Journal:  NPJ Precis Oncol       Date:  2018-07-25
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.